Pharma generics: Semaglutide patent expiry to open Rs 50bn opportunity; Indian players eye FY27 boost
Pharma generics: Semaglutide patent expiry to open Rs 50bn opportunity; Indian players eye FY27 boost
Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic drugmakers within 12-15 months. Indian companies like Alkem, Dr Reddy's, and Sun Pharma are set to benefit, with price drops expected to boost GLP-1 therapy adoption.
Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic drugmakers within 12-15 months. Indian companies like Alkem, Dr Reddy's, and Sun Pharma are set to benefit, with price drops expected to boost GLP-1 therapy adoption.
Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic drugmakers within 12-15 months. Indian companies like Alkem, Dr Reddy's, and Sun Pharma are set to benefit, with price drops expected to boost GLP-1 therapy adoption. 
